2023-04-27 13:25:01 ET
- Annovis Bio ( NYSE: ANVS ) said the U.S. Patent and Trademark Office (USPTO) granted a patent covering the use of buntanetap to prevent and treat diseases caused by the disruption in heavy metal homeostasis.
- The U.S. Patent No. 11,596,621 B2 is titled 'Prevention or Treatment of Disease States Due to Metal Dis-homeostasis Via Administration of Posiphen [buntanetap] to Healthy or Sick Humans' was issued on March 7.
- The patent, which would last till early 2040, is expected to cover use of buntanetap and its related analogue molecules to prevent and treat neurodegenerative diseases linked with metal dis-homeostasis.
- The company said that metal dis-homeostasis, particularly iron, is a hallmark of several conditions including neurodegenerative and cardiovascular diseases, cancer, and vital organ dysfunction.
- "The basis for this newly issued U.S. patent is the ability of buntanetap to augment the binding of IRP1 to mRNA under high iron conditions preventing the translation of neurotoxic proteins and restoring homeostasis," said Maria Maccecchini, founder, president and CEO of Annovis.
For further details see:
Annovis gets US patent linked to buntanetap for neurodegenerative diseases